KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Total Debt (2016 - 2025)

Historic Total Debt for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $45.1 billion.

  • Bristol Myers Squibb's Total Debt fell 914.02% to $45.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $45.1 billion, marking a year-over-year decrease of 914.02%. This contributed to the annual value of $45.1 billion for FY2025, which is 914.02% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported Total Debt of $45.1 billion as of Q4 2025, which was down 914.02% from $49.0 billion recorded in Q3 2025.
  • Bristol Myers Squibb's Total Debt's 5-year high stood at $55.7 billion during Q1 2024, with a 5-year trough of $37.6 billion in Q3 2023.
  • Its 5-year average for Total Debt is $45.0 billion, with a median of $45.0 billion in 2022.
  • In the last 5 years, Bristol Myers Squibb's Total Debt plummeted by 1588.1% in 2023 and then skyrocketed by 4717.68% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Total Debt stood at $44.6 billion in 2021, then dropped by 11.75% to $39.3 billion in 2022, then increased by 1.15% to $39.8 billion in 2023, then rose by 24.83% to $49.6 billion in 2024, then fell by 9.14% to $45.1 billion in 2025.
  • Its Total Debt stands at $45.1 billion for Q4 2025, versus $49.0 billion for Q3 2025 and $49.2 billion for Q2 2025.